Recursion Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-11-05
- Employees
- 500
- Market Cap
- $2.1B
- Website
- http://www.recursion.com
- Introduction
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
StockWatch: Will Expanding to Life Sciences Reverse AMD's Stock Decline?
AMD partners with Absci for AI drug discovery, investing $20M. Despite this, AMD's stock fell due to a downgrade by HSBC, citing Nvidia's dominance in GPUs. Nvidia continues to expand in life sciences, contrasting with AMD's challenges in the AI GPU market.
How AI uncovers new ways to tackle difficult diseases
AI is revolutionizing drug discovery, with companies like Insilico Medicine using generative AI to design drugs faster and more efficiently. AI helps identify therapeutic targets and design molecules, reducing time and costs. Despite challenges like data limitations, AI-discovered molecules are entering clinical trials, promising a new era in medicine.
Top 5 Emerging Trends in Life Science and Biotech for 2025
2025 marks a pivotal year for life sciences and biotech, with AI in drug discovery, synthetic biology, personalized medicine, cell and gene therapies, and green biotech leading transformative innovations. These advancements promise to revolutionize healthcare, agriculture, and environmental sustainability, despite challenges in accessibility, scalability, and ethics.
Recursion Pharmaceuticals Announces 2 Key Clinical Trial Clearances
Recursion announced MHRA cleared a Phase 1 trial for REC-3565, a MALT1 inhibitor for B-cell malignancies, targeting ~41,000 R/R patients annually in US+EU5. FDA also cleared a Phase 1/2 trial for REC-4539, a reversible, CNS-penetrant LSD1 inhibitor for SCLC, targeting ~45,000 patients annually in US+EU5.
Recursion Advances Two Cancer Drug Trials
Recursion Pharmaceuticals advances clinical trials for cancer drugs REC-3565 and REC-4539, targeting B-cell malignancies and small-cell lung cancer, respectively. With strong financials and AI-driven drug discovery, the company aims to develop first- and best-in-class oncology treatments, supported by regulatory approvals and positive preclinical results.
Recursion Secures Dual Regulatory Green Light for REC-3565 and REC-4539 Clinical Trials
Recursion advances REC-3565, a MALT1 inhibitor for hematologic malignancies, and REC-4539, a reversible LSD1 inhibitor for small-cell lung cancer, into clinical trials. REC-3565 aims to reduce hyperbilirubinemia risk, while REC-4539 targets both peripheral disease and brain metastases, addressing unmet needs in oncology.
AI Accelerates and Expands Drug Development
AI is revolutionizing drug development, with companies like Genesis Therapeutics, Exscientia, Insilico Medicine, and Iambic Therapeutics leveraging AI for drug discovery. These firms use AI to identify and optimize small molecules for treating diseases, including cancer and fibrosis, aiming to accelerate drug development and reduce costs. AI platforms like GEMS, generative AI, and multimodal transformers are key to their success, enabling efficient exploration of chemical spaces and prediction of drug properties.
Recursion Announces Two Key Investigational Oncology Developments
Recursion announced MHRA and FDA clearances for Phase 1 trials of REC-3565, a MALT1 inhibitor for B-cell malignancies, and REC-4539, a reversible LSD1 inhibitor for small-cell lung cancer. REC-3565 aims to reduce hyperbilirubinemia risk, while REC-4539 targets both peripheral disease and brain metastases, addressing unmet needs in oncology.
Recursion Pharmaceuticals, Inc. Doses First Patient in Phase 2 Study of REC-3964 for Recurrent Clostridioides difficile Infection
Recursion has dosed the first patient in a Phase 2 study of REC-3964, a novel, oral, non-antibiotic small molecule targeting recurrent Clostridioides difficile infection by inhibiting toxin activity. REC-3964, developed using RecursionOS, offers a new treatment approach for a condition affecting up to 175,000 annually in the U.S., with over 29,000 deaths.
© Copyright 2025. All Rights Reserved by MedPath